4Drusano GL,Preston SL,Hardalo C,et al.Use of preclinical data for selection of a phase Ⅱ/Ⅲ dose for evernimicin and identification of a preclinical MIC breakpoint[J].Antimicrob Agents Chemother,2001;45:13-22.
5Ambrose PG,Bhavnani SM,Rubino CM,et al.Pharmacokinetics-pharmacodynamics of antimicrobial therapy:it's not just for mice anymore[J].Clin Infect Dis,2007;44:79-86.
6Drusano GL.Antimicrobial pharmacodynamics:critical interactions of 'bug and drug'[J].Nat Rev Microbiol,2004;2:289-300.
7Merrikin DJ,Briant J,Rolinson GN.Effect of protein binding on antibiotic activity in vivo[J].J Antimicrob Chemother,1983;11:233-238.
8Mueller M,de la Pena A,Derendorf H.Issues in pharmacokinetics and pharmacodynamics of anti-infective agents:kill curves versus MIC[J].Antimicrob Agents Chemother,2004;48:369-377.
9Cheung BW,Liu W,Ji P,et al.The chinchilla microdialysis model for the study of antibiotic distribution to middle ear fluid[J].AAPS J,2006;8:E41-E47.
10Andes D,Craig WA.Animal model pharmacokinetics and pharmacodynamics:a critical review[J].Int J Antimicrob Agents,2002;19:261-268.
